Luis A Diaz

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi request reprint The current clinical value of genomic instability
    Luis A Diaz
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Avenue, Baustein Bunting Cancer Research Building, Room 520, Baltimore, MD 21231, USA
    Semin Cancer Biol 15:67-71. 2005
  2. pmc The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
    Luis A Diaz
    Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21287, USA
    Nature 486:537-40. 2012
  3. pmc Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells
    Jihye Yun
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 325:1555-9. 2009
  4. ncbi request reprint Serial assessment of human tumor burdens in mice by the analysis of circulating DNA
    Carlo Rago
    The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute, Baltimore, Maryland, USA
    Cancer Res 67:9364-70. 2007
  5. pmc A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
    Surojit Sur
    The Howard Hughes Medical Institute and The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 106:3964-9. 2009
  6. pmc Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making
    Hari Nathan
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 19:3668-76. 2012
  7. pmc Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
    Mark Sausen
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Nat Genet 45:12-7. 2013
  8. pmc Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways
    Jian Wu
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 108:21188-93. 2011
  9. ncbi request reprint The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT
    Chetan Bettegowda
    The Howard Hughes Medical Institute, The Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Biotechnol 24:1573-80. 2006
  10. ncbi request reprint A bacterial protein enhances the release and efficacy of liposomal cancer drugs
    Ian Cheong
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Science 314:1308-11. 2006

Detail Information

Publications48

  1. ncbi request reprint The current clinical value of genomic instability
    Luis A Diaz
    Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Avenue, Baustein Bunting Cancer Research Building, Room 520, Baltimore, MD 21231, USA
    Semin Cancer Biol 15:67-71. 2005
    ..Whether the mechanisms resulting in the accumulation of genetic lesions can be translated and used clinically remains to be seen...
  2. pmc The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
    Luis A Diaz
    Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21287, USA
    Nature 486:537-40. 2012
    ..They explain why solid tumours develop resistance to targeted therapies in a highly reproducible fashion...
  3. pmc Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells
    Jihye Yun
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 325:1555-9. 2009
    ..Together, these data suggest that glucose deprivation can drive the acquisition of KRAS pathway mutations in human tumors...
  4. ncbi request reprint Serial assessment of human tumor burdens in mice by the analysis of circulating DNA
    Carlo Rago
    The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute, Baltimore, Maryland, USA
    Cancer Res 67:9364-70. 2007
    ..A marked, transient spike in circulating human tumor DNA occurred immediately after cytotoxic therapy or surgery. This simple assay may find broad utility in target validation studies and preclinical drug development programs...
  5. pmc A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
    Surojit Sur
    The Howard Hughes Medical Institute and The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 106:3964-9. 2009
    ..This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro...
  6. pmc Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making
    Hari Nathan
    Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    Ann Surg Oncol 19:3668-76. 2012
    ..Criteria for resectability of colon cancer liver metastases (CLM) are evolving, yet little is known about how physicians choose a therapeutic strategy for potentially resectable CLM...
  7. pmc Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
    Mark Sausen
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Nat Genet 45:12-7. 2013
    ..These results highlight the dysregulation of chromatin remodeling in pediatric tumorigenesis and provide new approaches for the management of patients with neuroblastoma...
  8. pmc Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways
    Jian Wu
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 108:21188-93. 2011
    ..These results highlight the essential role of ubiquitin ligases in these neoplasms and have important implications for the diagnosis and treatment of patients with cystic tumors...
  9. ncbi request reprint The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT
    Chetan Bettegowda
    The Howard Hughes Medical Institute, The Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, Department of Pharmacology and Molecular Sciences, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Biotechnol 24:1573-80. 2006
    ..Through this analysis, we found that C. novyi-NT spores contained mRNA and that the spore transcripts were distinct from those in vegetative forms of the bacterium...
  10. ncbi request reprint A bacterial protein enhances the release and efficacy of liposomal cancer drugs
    Ian Cheong
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
    Science 314:1308-11. 2006
    ..This protein could potentially be incorporated into diverse experimental approaches for the specific delivery of chemotherapeutic agents to tumors...
  11. pmc Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing
    Rebecca J Leary
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287, USA
    Sci Transl Med 4:162ra154. 2012
    ..Given that chromosomal abnormalities are present in nearly all human cancers, this approach represents a useful method for the noninvasive detection of human tumors that is not dependent on the availability of tumor biopsies...
  12. pmc Circulating mutant DNA to assess tumor dynamics
    Frank Diehl
    The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Nat Med 14:985-90. 2008
    ..We suggest that this personalized genetic approach could be generally applied to individuals with other types of cancer...
  13. pmc Cancer genome landscapes
    Bert Vogelstein
    The Ludwig Center and The Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287, USA
    Science 339:1546-58. 2013
    ..Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality...
  14. ncbi request reprint Targeting cancer with bugs and liposomes: ready, aim, fire
    Ian Cheong
    The Ludwig Center for Cancer Genetics and Therapeutics at the Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, Maryland 21231, USA
    Cancer Res 67:9605-8. 2007
    ..This article will highlight the recent advance in using a novel lipase secreted by the tumor-colonizing anaerobic bacterium Clostridium novyi-NT to induce the targeted release of liposomal payloads within tumors...
  15. pmc Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, The Johns Hopkins Kimmel Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Oncotarget 3:709-22. 2012
    ....
  16. pmc Detection of tumor DNA at the margins of colorectal cancer liver metastasis
    Matthias Holdhoff
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland, USA
    Clin Cancer Res 17:3551-7. 2011
    ..Defining an adequate resection margin of colorectal cancer liver metastases is essential for optimizing surgical technique. We have attempted to evaluate the resection margin through a combination of histopathologic and genetic analyses...
  17. doi request reprint Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas
    Matthias Holdhoff
    Brain Cancer Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
    J Neurooncol 110:279-85. 2012
    ..Molecular markers that are likely to affect patient care should be ordered with the goal to maximize benefit for patients and to avoid non-actionable results and additional costs...
  18. pmc Sensitive digital quantification of DNA methylation in clinical samples
    Meng Li
    The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Nat Biotechnol 27:858-63. 2009
    ..In addition to diagnostic and prognostic applications, this digital quantification of rare methylation events should be applicable to preclinical assessment of new epigenetic biomarkers and quantitative analyses in epigenetic research...
  19. pmc IgH gene rearrangements as plasma biomarkers in Non- Hodgkin's lymphoma patients
    Jian He
    The Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    Oncotarget 2:178-85. 2011
    ..IgCap may enable a more informed management of selected patients with NHL and other B-cell malignancies in the future...
  20. pmc Genetically defined subsets of human pancreatic cancer show unique in vitro chemosensitivity
    YunFeng Cui
    Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 18:6519-30. 2012
    ..Chemotherapy for pancreatic cancer might be improved by adjusting it to individual genetic profiles. We attempt to identify genetic predictors of chemosensitivity to broad classes of anticancer drugs...
  21. pmc Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development
    Jian Wu
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Sci Transl Med 3:92ra66. 2011
    ..In addition to defining a new pathway for pancreatic neoplasia, these data suggest that GNAS mutations can inform the diagnosis and management of patients with cystic pancreatic lesions...
  22. pmc A robust approach to enhance tumor-selective accumulation of nanoparticles
    Yuan Qiao
    The Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and Sidney Kimmel Cancer Center at the Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Oncotarget 2:59-68. 2011
    ....
  23. pmc Detection of circulating tumor DNA in early- and late-stage human malignancies
    Chetan Bettegowda
    Ludwig Center for Cancer Genetics and Therapeutics, Howard Hughes Medical Institute and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Sci Transl Med 6:224ra24. 2014
    ..Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer. ..
  24. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
    ..014) and enhancement of the T-cell repertoire (P = 0.031). In conclusion, checkpoint blockade in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study...
  25. pmc The colorectal microRNAome
    Jordan M Cummins
    The Sidney Kimmel Comprehensive Cancer Center and Howard Hughes Medical Institute, Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 103:3687-92. 2006
    ..These studies suggest that the human genome contains many more miRNAs than currently identified and provide an approach for the large-scale experimental cloning of novel human miRNAs in human tissues...
  26. pmc Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers
    Isaac Kinde
    The Ludwig Center for Cancer Genetics and Therapeutics, The Swim Across America Laboratory at Johns Hopkins, Baltimore, MD 21287, USA
    Sci Transl Med 5:167ra4. 2013
    ..Although improvements need to be made before applying this test in a routine clinical manner, it represents a promising step toward a broadly applicable screening methodology for the early detection of gynecologic malignancies...
  27. ncbi request reprint Pharmacologic and toxicologic evaluation of C. novyi-NT spores
    Luis A Diaz
    Howard Hughes Medical Institute, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Toxicol Sci 88:562-75. 2005
    ..However, there was no laboratory or histopathologic evidence of sepsis, and the toxicity could be effectively controlled by simple hydration...
  28. pmc An integrated genomic analysis of human glioblastoma multiforme
    D Williams Parsons
    Ludwig Center for Cancer Genetics and Therapeutics, and Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 321:1807-12. 2008
    ..These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs...
  29. pmc A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram
    Trevor A Ellison
    Departments of Surgery Pathology Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Md Vanderbilt University Medical Center, Department of Pathology, Microbiology and Immunology, Nashville, TN The Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, Baltimore, MD and The University of Colorado, Department of Surgery, Aurora, CO
    Ann Surg 259:204-12. 2014
    ....
  30. pmc DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors
    Yuchen Jiao
    Ludwig Center for Cancer Genetics and Howard Hughes Medical Institutions, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 331:1199-203. 2011
    ..We also found mutations in genes in the mTOR (mammalian target of rapamycin) pathway in 14% of the tumors, a finding that could potentially be used to stratify patients for treatment with mTOR inhibitors...
  31. ncbi request reprint Digital quantification of mutant DNA in cancer patients
    Frank Diehl
    The Ludwig Center for Cancer Genetics and Therapeutics, The Johns Hopkins Kimmel Cancer Center, 1650 Orleans Street, Room 590, Baltimore, MD 21231, USA
    Curr Opin Oncol 19:36-42. 2007
    ..Here we discuss technologies available for the detection and quantification of mutant DNA in clinical samples and the value of such measurements for patient management...
  32. pmc Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer
    Nilofer Azad
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Bldg, Room 1M52, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Invest New Drugs 31:345-54. 2013
    ..v. days 1, 8; cetuximab 400 mg/m(2) i.v. days 1 and 250 mg/m(2) i.v. weekly; and sorafenib 400 mg orally twice daily in advanced, pretreated CRC. The combination resulted in a modest response rate...
  33. pmc Systemic use of tumor necrosis factor alpha as an anticancer agent
    Nicholas J Roberts
    Ludwig Center for Cancer Genetics and Therapeutics, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University, Baltimore, MD 21231, USA
    Oncotarget 2:739-51. 2011
    ..Also discussed, based on recent preclinical data, is a potential future role of systemic TNF-α in combination with liposomal chemotherapy to facilitate increased drug uptake into tumors...
  34. pmc Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma
    Sian Jones
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Science 330:228-31. 2010
    ..In a total of 42 OCCCs, 7% had mutations in PPP2R1A and 57% had mutations in ARID1A. These results suggest that aberrant chromatin remodeling contributes to the pathogenesis of OCCC...
  35. pmc Detection and quantification of mutations in the plasma of patients with colorectal tumors
    Frank Diehl
    Howard Hughes Medical Institute and The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, 1650 Orleans Street, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 102:16368-73. 2005
    ..01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon...
  36. ncbi request reprint Cancer drug discovery through collaboration
    Christoph Lengauer
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Rev Drug Discov 4:375-80. 2005
    ..We suggest that by merging and organizing their core competencies, academia, biotechnology companies and the pharmaceutical industry can address existing bottlenecks in anticancer drug discovery and development...
  37. pmc Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients
    Tian Li Wang
    The Howard Hughes Medical Institute, Sidney Kimmel Comprehensive Cancer Center and Department of Surgery, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Proc Natl Acad Sci U S A 101:3089-94. 2004
    ..01). These data suggest that genetic amplification of TYMS is a major mechanism of 5-FU resistance in vivo and have important implications for the management of colorectal cancer patients with recurrent disease...
  38. pmc Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, MD, USA
    J Clin Oncol 26:3503-10. 2008
    ..To examine the efficacy of adjuvant chemoradiotherapy after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PC) in patients undergoing resection at Johns Hopkins Hospital (JHH; Baltimore, MD)...
  39. ncbi request reprint Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer
    Katherine Y Fan
    From the aDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Statistics, Stanford University, Palo Alto, California cDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California and dDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, eDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, fRussell H Morgan Department of Radiology and Radiological Sciences, gDivision of Endocrinology and Metabolism, Department of Internal Medicine, and hDepartment of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Natl Compr Canc Netw 12:50-7. 2014
    ..5% or greater influence OS of patients with PDA even when accounting for other known prognostic factors. HbA1c level at presentation is significantly higher in patients with PDA than patients with BPD and seems to affect survival. ..
  40. pmc A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 69:415-24. 2012
    ..We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma...
  41. pmc Heteroplasmic mitochondrial DNA mutations in normal and tumour cells
    Yiping He
    The Ludwig Center for Cancer Genetics and Therapeutics and The Howard Hughes Medical Institute at The Johns Hopkins Kimmel Cancer Center, Baltimore, Maryland 21231, USA
    Nature 464:610-4. 2010
    ..In particular, they demonstrate that individual humans are characterized by a complex mixture of related mitochondrial genotypes rather than a single genotype...
  42. pmc Development of personalized tumor biomarkers using massively parallel sequencing
    Rebecca J Leary
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Sci Transl Med 2:20ra14. 2010
    ..This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients...
  43. doi request reprint Disappearing colorectal liver metastases after chemotherapy: should we be concerned?
    Mark G Van Vledder
    Department of Surgery and Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
    J Gastrointest Surg 14:1691-700. 2010
    ..With increasing efficacy of preoperative chemotherapy for colorectal cancer, more patients will present with one or more disappearing liver metastases (DLM) on preoperative cross-sectional imaging...
  44. pmc Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas
    Hatim Husain
    Brain Cancer Program, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Cancer Research Building II, 1550 Orleans Street, 1M 16, Baltimore, MD, 21287, USA
    J Neurooncol 109:123-7. 2012
    ..GFAP remains a potentially informative plasma biomarker for gliomas. Longitudinal studies are required to correlate pGFAP levels with patient outcomes...
  45. pmc The impact of insurance on access to cancer clinical trials at a comprehensive cancer center
    Justin F Klamerus
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 16:5997-6003. 2010
    ..We sought to explore the impact of insurance clearance on disparities in access to cancer clinical trials at this urban comprehensive cancer center...
  46. ncbi request reprint Mutant PIK3CA promotes cell growth and invasion of human cancer cells
    Yardena Samuels
    The Sidney Kimmel Comprehensive Cancer Center and The Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA
    Cancer Cell 7:561-73. 2005
    ..Treatment with the PI3K inhibitor LY294002 abrogated PIK3CA signaling and preferentially inhibited growth of PIK3CA mutant cells. These data have important implications for therapy of cancers harboring PIK3CA alterations...
  47. pmc Understanding the enemy
    Victor E Velculescu
    Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287, USA
    Sci Transl Med 3:98ps37. 2011
    ..This molecular information is the latest in a series of genetic discoveries that aid in cancer diagnosis and may pave the way to targeted therapeutic agents...
  48. ncbi request reprint Contribution of bone marrow-derived endothelial cells to human tumor vasculature
    Brock A Peters
    The Sidney Kimmel Comprehensive Cancer Center and Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA
    Nat Med 11:261-2. 2005
    ..These results illustrate substantial differences between human tumors and many mouse models with respect to angiogenesis and have important implications for the translation of experimental antiangiogenic therapies to the clinic...